A Mini-Review Describes the Analytical Aspects of Liquid chromatography – Mass spectrometry (LC-MS) Methods Aimed at Quantification of Stroma Liquid Biopsy™ Proteins in Body Fluids Biotech Support Group (BSG) reports on joint publication with authors from research collaborators at Leiden University Medical Center, describing the developmental and analytical aspects of Tier 2 LC-MRM-MS protein quantification methods News Release
A Mini-Review Describes the Analytical Aspects of Liquid chromatography – Mass spectrometry (LC-MS) Methods Aimed at Quantification of Stroma Liquid Biopsy™ Proteins in Body Fluids
MONMOUTH
JUNCTION, NJ, January
9, 2023 -- Biotech Support Group (BSG) reports on joint publication
with authors from research collaborators at Leiden
University Medical Center,
describing
the developmental and analytical aspects of
Tier 2 LC-MRM-MS protein quantification methods for liquid biopsies,
with a special focus on BSG’s Stroma Liquid Biopsy™ protein
panel. The
citation is: In the pursuit of personalized diagnostics and tailored treatments, quantitative protein tests contribute to a more precise definition of health and disease, driven by unmet clinical needs. Internationally standardized TNM classifications of malignant tumors are beneficial for diagnosis, however treatment outcome and survival of cancer patients is poorly predicted. To this end, the importance of the tumor microenvironment (TME) has endorsed the introduction of the tumor-stroma ratio as a prognostic parameter in solid primary tumor types, determined via routine diagnostic pathology slides. However, with the development of liquid chromatography – mass spectrometry (LC-MS) methods we aim at quantification of tumor-stroma specific proteins in body fluids, as the TME comprises a dynamic ecosystem of cellular and subcellular interactions that surrounds malignant cells, essential to tumor progression. The article states “Despite significant advances in malignant cell-derived biomarkers, such as circulating tumor cells (CTCs) and circulating cell-free tumor DNA (ctDNA), the TME has remained surprisingly underappreciated in current liquid biopsy research. To address TME profiling in liquid biopsy, the Stroma Liquid Biopsy™ (SLB) panel was developed as an experimental stroma-oriented proteomics alternative to the conventional genomic liquid biopsy biomarkers in oncology”.
“The SLB panel comprises a set of key proteins in interconnected stromal pathways (e.g. coagulation, acute phase inflammation) and is believed to capture a deranged systemic response to the presence of cancer in a plasma proteome blueprint. Remarkably, we recently demonstrated that the representing genes of the SLB protein panel compose expression signatures that are expressed in malignant cells and the non-malignant cells within the TME in colon cancer. Plasma protein levels of the SLB panel may, therefore, reflect histologic intratumoral stromal content and provide valuable prognostic information in liquid biopsies.”. A Tier 2 liquid chromatography multiple reaction monitoring mass spectrometry (LC-MRM-MS) assay, to identify and quantify proteins from the SLB panel requires well-defined selectivity, repeatability, sensitivity, and reproducibility and is the optimal choice for analytical performance of potential biomarkers. In this mini-review the analytical aspect of this developmental trajectory is further detailed. |
- About
- Products
- Hemoglobin Removal Kits
- Lipid Removal & Clarification
- Urine Protein & Low Abundance Enrichment
- Class Specific Enrichment
- Sample Prep Mass Spectrometry
- Functional & Chemical Proteomics
- Genomic Sample Prep
- Accessories
- Technical Resources
- References
- Publications & Reports
- FAQs
- Case Studies
- BSG Products To Assist in Analyzing Macrophage Polarization
- Ectodomain Shedding and Enrichment of the Soluble Membrane Proteome
- Investigate out of the Venn Diagram box
- Methods to selectively deplete or purify Hemoglobin from Dried Blood Spots (DBS)
- The Utility of HemoVoid™ is Demonstrated in 3 Proteomic Investigations Identifying Potential Disease Specific Biomarkers
- The 4 common features of our sample prep products, known as the BSG Advantage, are highlighted in a selection of journal references.
- AlbuVoid™ Workflows Advance Cell Secretome Proteomics
- Lipid Removal for Phenotypic Cell Response in Cancer Research
- The Influence of Sample Prep Bias on LC-MS Targeted Peptide Quantification in Serum Proteomics
- Re-imagining proteomics for developing precision medicine biomarkers of the innate immune response in SARS-CoV-2
- Patent Application Describes New Proteomic Methods to Monitor Protease Inhibitor Function During Covid-19 Infections
- Efficient Hemoglobin Removal Advances Red Cell Proteomics Offering Many New Insights Into Inflammation and Infectious Disease
- The Potential for New Blood Biomarkers in the Management of COVID-19 Disease
- Establishing the Utility of HemoVoid™ and HemogloBind™ as Enrichment Tools for Proteomic Analysis of Red Cells and Whole Blood in Parkinson’s Disease
- Species Diversity Supported By BSG Products
- Poster Report Describes Loss of Functional Serpin Activity In Cancer Patient Blood
- AlbuVoid™️ PLUS & AlbuSorb™️ PLUS Evaluating Different Windows of Observation Solves The Many Challenges of Serum Proteomics
- Tackling the Challenges of Serum Proteomics
- Lipid Removal Sample Prep for Cell Response Applications
- Sample Prep for Proteomic Analysis of Saliva
- Biotech Support Group Featured in Book, "Functional Proteomics – Methods and Protocols"
- Sample Prep Liquid Biopsy Products Suitable for Proteomic Profiling of a Variety of Body Fluid Sample Types
- Albumin and High Abundance Depletion
- Using HemogloBind™ as a Hemoglobin Binding Reagent
- Diverse technologies available for researchers to selectively bind or enrich exosomes and extracellular vesicles.
- Stroma Liquid Biopsy™ Biomarkers Profile Pan-Cancer Dysregulation of the Serum Proteome
- Diverse Depletion and Enrichment Technologies Enhance Simplicity and Efficiency of Obtaining Quality Proteomic Information
- Use On-Bead Digestion to Improve Time Required for Serum Digestion
- Using AlbuVoid™ as a Serum Protein Enrichment Kit in Functional Proteomics
- Using Cleanascite™ as a Lipid Absorption and Clarification Reagent
- Using HemoVoid to Remove Hemoglobin Before Analysis
- Contact
- Liquid Biopsy